Table 3.
Impact of HDAC schedules on hematological recovery
| HDAC-123, n = 92 (41.6%) | HDAC-135, n = 129 (58.4%) | P | |
|---|---|---|---|
| WBC >1.0 × 109/L recovery, median (IQR), d | |||
| Cycle 1 | 14 (13.0-15.0) | 17 (16.0-19.0) | <.0001 |
| Cycle 2 | 16 (15.0-17.0) | 19 (17.0-22.0) | <.0001 |
| Cycle 3 | 15 (15.0-17.0) | 19 (17.0-20.0) | <.0001 |
| Platelets >50.0 × 109/L recovery, median (IQR), d | |||
| Cycle 1 | 16 (15.0, 26.0) | 20 (18.0, 23.0) | .16 |
| Cycle 2 | 18 (16.0, 27.0) | 22 (19.0, 25.0) | .06 |
| Cycle 3 | 16 (16.0, 22.0) | 20 (19.0, 25.0) | <.01 |
| Neutrophils >0.5 × 109/L recovery, median (IQR), d | |||
| Cycle 1 | 15 (14.0, 16.0) | 18 (17.0, 20.0) | <.0001 |
| Cycle 2 | 16 (15.0, 17.0) | 20 (18.0, 22.0) | <.0001 |
| Cycle 3 | 16 (15.0, 17.0) | 19 (17.0, 21.0) | <.0001 |
| Delay between chemotherapies, median (IQR), d | |||
| Induction-cycle 1 | 41 (37.0, 50.0) | 42 (39.0, 49.0) | .61 |
| Cycle 1-cycle 2 | 36 (33.0, 42.5) | 37 (35.0, 44.0) | .07 |
| Cycle 2-cycle 3 | 37 (34.5, 50.5) | 39 (36.0, 47.0) | .54 |